Non-invasive Prenatal Testing Market: Global Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2016 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Non-Invasive Prenatal Testing Market: Product Type (Consumables and Reagents, Instruments), By End User (Public Labs, Private Labs), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Non-invasive Prenatal Testing Market Size was valued at USD 3.4 billion in 2021 and is projected to reach USD 6.5 billion by 2028 at a CAGR of 9.8% during the forecast period 2022 to 2028. Noninvasive prenatal testing is a new type of genetic testing that is used to screen birth defects and inherited diseases. This test is also known as the cell-free DNA screening. The procedures include both non-invasive techniques and invasive techniques. In non-invasive techniques, serum screening and ultrasonography are included. Whereas, in invasive techniques amniocentesis and chorionic villus sampling are included. Most of the healthcare professionals prefer the non-invasive techniques over invasive, as the invasive techniques have higher risk quotient, also sometimes leads to fetal loss. Noninvasive prenatal testing are the innovative testing procedures that uses cell-free circulating fetal DNA in the maternal serum to screen for more common fetal aneuploidies, such as trisomy 21, trisomy 18 (Edward syndrome), trisomy 13 (Patau syndrome), and monosomy X (Turner syndrome). Increasing prevalence of these genetic disorders are likely to drive the market for non-invasive prenatal testing over the forecast period. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. The major market participants are adopting the strategies such as mergers and acquisitions to position themselves as strong players. In February 2018, BD (Becton, Dickinson and Company) announced the commercial availability of the CE-IVD marked PAXgene Blood ccfDNA tube within the European Economic Area and Switzerland (Western Europe).

Noninvasive Prenatal Testing Market

MARKET SUMMARY
-
9.8% CAGR
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR–9.8%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Noninvasive Prenatal Testing Market

  • The noninvasive prenatal testing market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The noninvasive prenatal testing market is segmented based on product type, end user and geography.
Market Leaders
  • PerkinElmer, Inc. (U.S.)
  • QIAGEN N.V. (Germany)
  • Agilent Technologies, Inc. (U.S.)
  • GE Healthcare (U.S.)
  • Koninklijke Philips N.V. (Netherlands)
Noninvasive Prenatal Testing Market

Drivers and Restraints

The rising awareness among parents, adoption toward IVF procedures is driving the market. In birth outcomes such as birth defects, newborn weight, and multiple births, maternal age plays a major role. The average age at which women are giving first birth has been increasing. As per Centre for Disease Control and Prevention (CDC) report, the mean age of a women at first birth was 25.8 years in 2012, and it has increased to 26 years in 2013, in the U.S. In addition to that, according to the World Health Organization (WHO), about 3,000 to 5,000 children are born with chromosome disorder, approximately 60%-80% of the children with Down syndrome have hearing deficit, and 40%-45% have congenital heart disease. The rise in the prevalence of these genetic disorders is likely to drive the market for non-invasive prenatal testing market.


Noninvasive Prenatal Testing Market

North America dominates the market

North America dominates the noninvasive prenatal testing market due to growing adoption of advanced diagnostics in the region and increase in the access to various prenatal testing procedures. North America is expected to hold the largest revenue share over the forecast period. Followed by the North America are the regions of Europe and Asia Pacific. The countries such as India and China are predicted to drive the market in Asia-Pacific region due to favorable population demographics.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Noninvasive Prenatal Testing Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content

1. Executive Summary
2. Global Non-Invasive Prenatal Testing Market Introduction
2.1. Global Non-Invasive Prenatal Testing Market – Taxonomy
2.2. Global Non-Invasive Prenatal Testing Market –Definitions
2.2.1. By Product Type
2.2.2. By End User
2.2.3. By Region
3. Global Non-Invasive Prenatal Testing Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Non-Invasive Prenatal Testing Market Dynamic Factors – Impact Analysis
3.6. Global Non-Invasive Prenatal Testing Market – Competition Landscape
4. Global Non-Invasive Prenatal Testing Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Non-Invasive Prenatal Testing Market, By Product Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
5.1. Consumables and Reagents
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Instruments
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
6. Global Non-Invasive Prenatal Testing Market, By End User, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
6.1. Public Labs
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Private Labs
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. Global Non-Invasive Prenatal Testing Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
7.1. North America
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Non-Invasive Prenatal Testing Market – Opportunity Analysis Index, By Product Type, End User, and Region, 2022 – 2028
8. North America Non-Invasive Prenatal Testing Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
8.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Consumables and Reagents
8.1.2. Instruments
8.2. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Public Labs
8.2.2. Private Labs
8.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. USA
8.3.2. Canada
8.4. North America Non-Invasive Prenatal Testing Market – Opportunity Analysis Index, By Product Type, End User, and Country, 2022 – 2028
8.5. North America Non-Invasive Prenatal Testing Market Dynamics – Trends
9. Europe Non-Invasive Prenatal Testing Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
9.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Consumables and Reagents
9.1.2. Instruments
9.2. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Public Labs
9.2.2. Private Labs
9.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Rest of Europe
9.4. Europe Non-Invasive Prenatal Testing Market – Opportunity Analysis Index, By Product Type, End User, and Country, 2022 – 2028
9.5. Europe Non-Invasive Prenatal Testing Market Dynamics – Trends
10. Asia-Pacific Non-Invasive Prenatal Testing Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
10.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Consumables and Reagents
10.1.2. Instruments
10.2. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Public Labs
10.2.2. Private Labs
10.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Non-Invasive Prenatal Testing Market – Opportunity Analysis Index, By Product Type, End User, and Country, 2022 – 2028
10.5. Asia-Pacific Non-Invasive Prenatal Testing Market Dynamics – Trends
11. Latin America Non-Invasive Prenatal Testing Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
11.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Consumables and Reagents
11.1.2. Instruments
11.2. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Public Labs
11.2.2. Private Labs
11.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Rest of Latin America
11.4. Latin America Non-Invasive Prenatal Testing Market – Opportunity Analysis Index, By Product Type, End User, and Country, 2022 – 2028
11.5. Latin America Non-Invasive Prenatal Testing Market Dynamics – Trends
12. Middle East and Africa Non-Invasive Prenatal Testing Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
12.1. Product Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Consumables and Reagents
12.1.2. Instruments
12.2. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Public Labs
12.2.2. Private Labs
12.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Non-Invasive Prenatal Testing Market – Opportunity Analysis Index, By Product Type, End User, and Country, 2022 – 2028
12.5. MEA Non-Invasive Prenatal Testing Market Dynamics – Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Product Type Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. F. Hoffmann-La Roche Ltd.
13.2.2. PerkinElmer Inc.
13.2.3. Natera, Inc.
13.2.4. BGI
13.2.5. Laboratory Corp. of America Holdings
13.2.6. Agilent Technologies
13.2.7. Centogene N.V.
13.2.8. Illumina, Inc.
13.2.9. Qiagen N.V.
13.2.10. Quest Diagnostics
14. Research Methodology
15. Key Assumptions and Acronyms

Report

Company Profile

  • PerkinElmer, Inc. (U.S.)
  • QIAGEN N.V. (Germany)
  • Becton, Dickinson and Company (U.S)
  • Agilent Technologies, Inc. (U.S.)
  • Beijing Genomics Institute (China)
  • GE Healthcare (U.S.)
  • Koninklijke Philips N.V. (Netherlands)
  • Illumina, Inc. (U.S.)
  • Thermo Fisher Scientific, Inc. (U.S.)
  • Hoffmann-La Roche Ltd. (Switzerland)
  • Pacific Biosciences of California, Inc. (U.S.)

Description

Non-invasive Prenatal Testing Market Size was valued at USD 3.4 billion in 2021 and is projected to reach USD 6.5 billion by 2028 at a CAGR of 9.8% during the forecast period 2022 to 2028. Noninvasive prenatal testing is a new type of genetic testing that is used to screen birth defects and inherited diseases. This test is also known as the cell-free DNA screening. The procedures include both non-invasive techniques and invasive techniques. In non-invasive techniques, serum screening and ultrasonography are included. Whereas, in invasive techniques amniocentesis and chorionic villus sampling are included. Most of the healthcare professionals prefer the non-invasive techniques over invasive, as the invasive techniques have higher risk quotient, also sometimes leads to fetal loss. Noninvasive prenatal testing are the innovative testing procedures that uses cell-free circulating fetal DNA in the maternal serum to screen for more common fetal aneuploidies, such as trisomy 21, trisomy 18 (Edward syndrome), trisomy 13 (Patau syndrome), and monosomy X (Turner syndrome). Increasing prevalence of these genetic disorders are likely to drive the market for non-invasive prenatal testing over the forecast period. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. The major market participants are adopting the strategies such as mergers and acquisitions to position themselves as strong players. In February 2018, BD (Becton, Dickinson and Company) announced the commercial availability of the CE-IVD marked PAXgene Blood ccfDNA tube within the European Economic Area and Switzerland (Western Europe).

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX